News | October 22, 2012

Resource Helps Advance Understanding of Cardiac Side Effects from Chemotherapy

October 22, 2012 — QuantiaMD, the largest online physician community, and The International CardiOncology Society (ICOS) announced at the ICOS 6th annual meeting in Milan, Italy a partnership to launch the ICOS global physicians collaboration forum on QuantiaMD. This first-of-its-kind partnership brings together an emerging area of medicine with QuantiaMD’s dynamic clinical exchange to rapidly drive awareness, education and training around the cardiac implications of oncology treatments.

ICOS was founded in 2009 by Dr. Carlo Cipolla (European Institute of Oncology, Milan, Italy) and Daniel Lenihan (while at MD Anderson Cancer Center, Houston, Texas) with a goal of eliminating cardiac disease as a barrier to optimal cancer therapy. Previously thought to be a relatively rare phenomenon, studies done by Cipolla and Lenihan suggest that as high as 20-30 percent of patients receiving certain classes of anticancer therapies may have some level of cardiac side effects. Cancer therapeutics, both radiation therapy and chemotherapy, are known to have important effects on the cardiovascular system. Many of these long-term consequences did not become clinically evident until overall cancer survival improved enough for the effects to be realized.

ICOS is leveraging QuantiaMD’s extensive physician membership, and its breakthrough media and communications platform, to engage clinicians via mobile devices and the web. QuantiaMD and ICOS are producing a series of concise, interactive patient cases and other resources, which QuantiaMD will distribute broadly to engage and educate all relevant clinicians. In addition, QuantiaMD’s leading technology platform is enabling new and effective ways of collaborating across this global group of oncologists and cardiologists from top centers such Vanderbilt, MD Anderson and Memorial Sloan Kettering. Presentations, including audio and PowerPoint from the 6th Annual Meeting, will be placed on QuantiaMD as soon as available, and previous proceedings of the Annual Meeting are already available.

Cardiac side effects, such as heart failure, can prevent patients from continuing to receive optimal cancer treatments, as well as impact long-term survival. “Many cardiac side effects can be more effectively managed, and, in some cases, prevented, with currently available therapies,” said Lenihan. “Much more investigation is needed, but it is critical that we raise the awareness among oncologists and cardiologists to ensure optimal management of these patients.”

There are no currently established medical guidelines for the care of adults who have survived cancer therapy, particularly as it relates to heart disease, and, specifically heart failure. Lenihan is using QuantiaMD’s secure Clinical Discussion feature to draft and refine the first set of clinical guidelines on this important topic, soliciting input from members of many professional societies including the Heart Failure Society of America, American College of Cardiology, European Society of Medical Oncology, American Society of Clinical Oncology and the European Society of Cardiology. In addition, ICOS will leverage QuantiaMD to disseminate important new data being released during its annual meeting as well as help to support clinical trial centers become more connected in the future.

“Traditional web approaches have not adequately expressed or augmented the dynamism of medical practice and research,” said Eric Schultz, chairman and CEO of QuantiaMD. “With ICOS, we hope to set a new paradigm for how physicians learn and collaborate within a secure environment in critical areas of patient care.”

For more information: www.cardioncology.com

 

Related Content

YITU Releases AI-Based Cancer Screening Solutions at RSNA 2018
News | Artificial Intelligence | December 06, 2018
Chinese artificial intelligence (AI) healthcare company YITU healthcare released two brand-new products, Intelligent...
Researchers Awarded 2018 Canon Medical Systems USA/RSNA Research Grants
News | Radiology Imaging | November 13, 2018
The Radiological Society of North America (RSNA) Research & Education (R&E) Foundation recently announced the...
University of Missouri Research Reactor First U.S. I-131 Supplier in 30 Years

MURR is the only supplier of I 131 in the United States and the first U.S. supplier since the 1980s. Image courtesy of University of Missouri

News | Radiopharmaceuticals and Tracers | November 13, 2018
The University of Missouri Research Reactor (MURR) recently shipped its first batch of Iodine-131 (I-131), a...
News | Advanced Visualization | November 13, 2018
Canon Medical Systems USA and Applied Radiology will host a pair of expert-led forums in high-resolution imaging and...
Videos | Radiation Oncology | November 06, 2018
Genomics can be used to assess a patient's radiosensitivity, which can be used to increase or decrease the radiation
Huntsman Cancer Institute Installs First Preclinical nanoScan 3T PET/MRI in U.S.
News | PET-MRI | October 10, 2018
The Center for Quantitative Cancer Imaging at Huntsman Cancer Institute (HCI) at the University of Utah in Salt Lake...
X-ray Mammography Adoption to Skyrocket for Breast Cancer Detection
News | Mammography | October 08, 2018
Highly populated countries have traditionally been slow adopters of non-conventional business models, but a new Frost...
Body Vision Medical Announces Release of LungVision
Technology | Lung Cancer | October 05, 2018
Body Vision Medical, a medical device company specializing in lung cancer diagnostics, announced the launch of its...
Leica Biosystems Launches MammoPort Specimen Containment and Transport System
Technology | Breast Biopsy Systems | October 03, 2018
Leica Biosystems announced the U.S. launch of MammoPort, the first integrated specimen containment and transport system...